Abstract
Purpose
[18F]Mefway is a positron emission tomography (PET) radioligand for quantification of the brain serotonin 1A (5-HT1A) receptor density. The purpose of this study was to evaluate the radiation safety of [18F]Mefway in humans.
Procedures
Six healthy volunteers (three males and three females) were whole-body PET scanned for 114 min after injection of [18F]Mefway (226 ± 35 MBq). Estimated radiation doses were determined by the OLINDA/EXM software.
Results
[18F]Mefway was safe and well tolerated by all subjects. Residence time ranges from 0 (gallbladder) to 0.822 h (urinary bladder wall). While the estimated radiation doses in the reproductive and blood-forming organs were below 13.35–22.87 μSv/MBq, radiation dose in the urinary bladder wall was 471 μSv/MBq. The mean effective dose was 40.23 ± 6.63 μSv/MBq.
Conclusion
For a typical single injection of 185 MBq (5 mCi), the dose will result in 87.1 mSv for the urinary bladder wall. To reduce radiation burden, the bladder voiding can be used before [18F]Mefway PET scan.
This is a preview of subscription content, log in via an institution to check access.
References
Lai MK, Tsang SW, Francis PT et al (2003) Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res 974:82–87
Drevets WC, Frank E, Price JC et al (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375–1387
Kepe V, Barrio JR, Huang SC et al (2006) Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci U S A 103:702–707
Kish SJ, Tong J, Hornykiewicz O et al (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131:120–131
Carson RE, Lang L, Watabe H et al (2000) PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol 27:493–497
Gunn RN, Sargent PA, Bench CJ et al (1998) Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 8:426–440
Lacan G, Plenevaux A, Rubins DJ et al (2008) Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 35:2256–2266
Mukherjee J, Bajwa AK, Wooten DW et al (2015) Comparative assessment of F-Mefway as a serotonin 5-HT receptor PET imaging agent across species- rodents, nonhuman primates, and humans. J Comp Neurol 524:1457–1471
Saigal N, Pichika R, Easwaramoorthy B et al (2006) Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J Nucl Med 47:1697–1706
Choi JY, Shin S, Lee M et al (2014) Acute physical stress induces the alteration of the serotonin 1A receptor density in the hippocampus. Synapse 68:363–368
Lee M, Ryu YH, Cho WG et al (2014) Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-[18F]Mefway. Appl Radiat Isot 94:30–34
Choi JY, Lyoo CH, Kim JS et al (2015) 18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY. PLoS One 10:e0121342
Hillmer AT, Wooten DW, Bajwa AK et al (2014) First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors. J Nucl Med 55:1973–1979
Shoup TM, Yokell DL, Rice PA et al (2013) A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. J Label Compd Radiopharm 56:736–740
Hines CS, Liow JS, Zanotti-Fregonara P et al (2011) Human biodistribution and dosimetry of 11C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PLoS One 6:e25309
Zanotti-Fregonara P, Lammertsma AA, Innis RB (2013) Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging 40:1781–1783
Constantinescu CC, Sevrioukov E, Garcia A et al (2013) Evaluation of [18F]Mefway biodistribution and dosimetry based on whole-body PET imaging of mice. Mol Imaging Biol 15:222–229
Parsey RV, Belanger MJ, Sullivan GM et al (2005) Biodistribution and radiation dosimetry of 11C-WAY100,635 in humans. J Nucl Med 46:614–619
Anjos DA, Etchebehere EC, Ramos CD et al (2007) 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 48:764–770
Diehl M, Manolopoulou M, Risse J et al (2004) Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide. Acta Med Austriaca 31:76–78
Koyama K, Okamura T, Kawabe J et al (2003) Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44:353–358
Miraldi F, Vesselle H, Faulhaber PF et al (1998) Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23:3–7
Acknowledgments
This research was supported by the Nuclear R&D Program of the National Research Foundation of Korea (Grant No. NRF-2015M2A2A7027110) and INHA UNIVERSITY Research Grant (INHA-52574). The authors would like to express their sincere gratitude to Tae Ho Song and Won Taek Lee (PET technologists) who managed all PET experiments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Choi, J.Y., Lyoo, C.H., Kim, J.S. et al. Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans. Mol Imaging Biol 18, 803–806 (2016). https://doi.org/10.1007/s11307-016-0955-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-016-0955-8